Human dopamine receptor subtypes?in vitro binding analysis using3H-SCH 23390 and3H-raclopride

1988 ◽  
Vol 73 (1) ◽  
pp. 7-21 ◽  
Author(s):  
H. Hall ◽  
L. Farde ◽  
G. Sedvall
1987 ◽  
Vol 92 (3) ◽  
pp. 278-284 ◽  
Author(s):  
L. Farde ◽  
C. Halldin ◽  
S. Stone-Elander ◽  
G. Sedvall

FEBS Letters ◽  
2003 ◽  
Vol 556 (1-3) ◽  
pp. 276-280 ◽  
Author(s):  
Arne Heydorn ◽  
Birgitte P Søndergaard ◽  
Niels Hadrup ◽  
Birgitte Holst ◽  
Carol Renfrew Haft ◽  
...  

LWT ◽  
2021 ◽  
pp. 112674
Author(s):  
Di Wu ◽  
Ran Duan ◽  
Lan Tang ◽  
Dian Zhou ◽  
Zhen Zeng ◽  
...  

2013 ◽  
Vol 195 (6) ◽  
pp. 1204-1213 ◽  
Author(s):  
A. Chateau ◽  
W. van Schaik ◽  
P. Joseph ◽  
L. D. Handke ◽  
S. M. McBride ◽  
...  

2021 ◽  
Author(s):  
Kirsten Tolentino ◽  
Viktoriya Mashinson ◽  
Anish Vadukoot ◽  
Corey Hopkins

Abstract: The dopamine receptor 4 (D4R) is highly expressed in both motor, associative and limbic subdivisions of the coritico-basal ganglia network. Due to the distribution in the brain, there is mounting evidence pointing to a role for the D4R in the modulation of this network and its subsequent involvement in L-DOPA induced dyskinesias in Parkinson’s disease. As part of our continued effort in the discovery of novel D4R antagonists, we report the discovery and characterization of a new 3- or 4-benzyloxypiperidine scaffold as D4R antagonists. We report several D4R selective compounds (>30-fold vs. other dopamine receptor subtypes) with improved in vitro and in vivo stability over previously reported D4R antagonists.


Sign in / Sign up

Export Citation Format

Share Document